TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Brief Summary: This study will assess the safety and efficacy of multiple daily dosing of oral LFF571 in patients who have moderate Clostridium difficile infections.


Options:
A: Arm Label: Cadazolid 250 mg; Type: EXPERIMENTAL; Interventions: Drug: Cadazolid, Drug: Placebo-matching vancomycin | Arm Label: Cadazolid 500 mg; Type: EXPERIMENTAL; Interventions: Drug: Cadazolid, Drug: Placebo-matching vancomycin | Arm Label: Cadazolid 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Cadazolid, Drug: Placebo-matching vancomycin | Arm Label: Vancomycin 125 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin, Drug: Placebo-matching cadazolid | Intervention Type: DRUG; Name: Cadazolid; Assigned to Arm(s): Cadazolid 1000 mg, Cadazolid 250 mg, Cadazolid 500 mg | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): Vancomycin 125 mg | Intervention Type: DRUG; Name: Placebo-matching cadazolid; Assigned to Arm(s): Vancomycin 125 mg | Intervention Type: DRUG; Name: Placebo-matching vancomycin; Assigned to Arm(s): Cadazolid 1000 mg, Cadazolid 250 mg, Cadazolid 500 mg
B: Intervention Type: DRUG; Name: tolevamer potassium-sodium (GT267-004); Assigned to Arm(s): N/A
C: Arm Label: LFF571 (POC); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: Vancomycin (POC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin (POC) | Arm Label: LFF571 Dose level 1 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: LFF571 Dose level 2 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: LFF571 Dose level 3 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: LFF571 Dose level 4 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Intervention Type: DRUG; Name: LFF571; Assigned to Arm(s): LFF571 (POC), LFF571 Dose level 1 (cohort 2), LFF571 Dose level 2 (cohort 2), LFF571 Dose level 3 (cohort 2), LFF571 Dose level 4 (cohort 2) | Intervention Type: DRUG; Name: Vancomycin (POC); Assigned to Arm(s): Vancomycin (POC)
D: Arm Label: Fresh FMT; Type: EXPERIMENTAL; Interventions: Biological: Fresh FMT | Arm Label: Frozen-and-Thawed FMT; Type: EXPERIMENTAL; Interventions: Biological: Frozen-and-Thawed FMT | Intervention Type: BIOLOGICAL; Name: Fresh FMT; Assigned to Arm(s): Fresh FMT | Intervention Type: BIOLOGICAL; Name: Frozen-and-Thawed FMT; Assigned to Arm(s): Frozen-and-Thawed FMT

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pressure Ulcer Multi-disciplinary Teams Via Telemedicine (PUMTT): A Cluster Pragmatic Randomised Controlled Trial in Long Term Care
Brief Summary: The purpose of this study is to evaluate the effectiveness of 'enhanced' multi-disciplinary wound care teams (MDTs) vs. 'usual' care teams in Long Term Care (LTC) facilities in Ontario for the treatment of pressure ulcers. LTC facilities with more than 100 beds that are within a 100 km distance from St. Mikes and have a problem with pressure ulcers will be asked to participate. A total of 10 LTC facilities will be randomly selected (i.e. selected by chance) from those that agree to participate.

The 'enhanced' MDT will be an Advance Practice Nurse(APN) with expertise in wound care who has direct access to the wound care team at St. Mikes. This APN will develop treatment plans in consultation with facility staff, providing targeted pressure ulcer treatment education on an ongoing, case by case basis. Care is supported by telemedicine with the use of digital photography and online communication between members of the care team.

This study is a stepped wedge randomized trial, meaning LTC facilities are assigned to a start date for this study totally by chance. Changes in healing rates, wound related pain, cost, number of new pressure ulcers, and number of wounds healed will be measured before, and after the APN is introduced to facilities. In order to gain more insight into how people felt about this model of care, interviews will be held with individuals and groups of staff at 5 randomly selected facilities before, during, and after the study has been completed.


Options:
A: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional Group; Type: EXPERIMENTAL; Interventions: Procedure: interprof ACT measures | Intervention Type: PROCEDURE; Name: interprof ACT measures; Assigned to Arm(s): Interventional Group
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedical support; Type: ACTIVE_COMPARATOR; Interventions: Other: Telemedical support | Intervention Type: OTHER; Name: Telemedical support; Assigned to Arm(s): Telemedical support
C: Arm Label: Multi-disciplinary wound care team; Type: EXPERIMENTAL; Interventions: Other: Exposure to multi-disciplinary wound care team | Intervention Type: OTHER; Name: Exposure to multi-disciplinary wound care team; Assigned to Arm(s): Multi-disciplinary wound care team
D: Arm Label: Advance Care Planning Program; Type: EXPERIMENTAL; Interventions: Other: Implementation of a complex regional Advance Care Planning program | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation of a complex regional Advance Care Planning program; Assigned to Arm(s): Advance Care Planning Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin Addition to Gonadotropins Ovarian Stimulation in High Responder Patients With PCOS Undergoing In-vitro Fertilization
Brief Summary: The use of metformin pre-treatment and co-administration was recently proposed in infertile women affected by polycystic ovary syndrome (PCOS) treated with gonadotropins.

Data from meta-analyses showed that metformin administration significantly reduced the stimulation length and the total dose of gonadotropins used in PCOS women undergoing gonadotropins stimulation for non in-vitro fertilization (IVF) cycles. On the other hand, in IVF cycles metformin was demonstrated to significantly reduce the ovarian hyperstimulation syndrome (OHSS) rate in infertile patients with PCOS treated with gonadotropins.

The metformin regulating effect on the ovarian response was also observed in a randomized controlled trial (RCT) on young non-obese insulin-resistant women with PCOS receiving gonadotropins for mono-ovulation induction. In particular, metformin increased the mono-ovulatory cycles, the duration of stimulation and the amount of gonadotropins used, while it reduced the number of dominant follicles and the estradiol (E2) levels.

The aim of the present study was to evaluate the effect of metformin administration in high responder PCOS patients undergoing gonadotropins ovarian stimulation for IVF cycles.


Options:
A: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo administration | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Experimental group | Intervention Type: DRUG; Name: Placebo administration; Assigned to Arm(s): Control group
B: Arm Label: Metformin-treated group; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin-treated group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: M: Metformin P: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Metformin / Placebo treatment for 4 months | Intervention Type: DRUG; Name: Metformin / Placebo treatment for 4 months; Assigned to Arm(s): M: Metformin P: Placebo
D: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin Addition to Gonadotropins Ovarian Stimulation in High Responder Patients With PCOS Undergoing In-vitro Fertilization
Brief Summary: The use of metformin pre-treatment and co-administration was recently proposed in infertile women affected by polycystic ovary syndrome (PCOS) treated with gonadotropins.

Data from meta-analyses showed that metformin administration significantly reduced the stimulation length and the total dose of gonadotropins used in PCOS women undergoing gonadotropins stimulation for non in-vitro fertilization (IVF) cycles. On the other hand, in IVF cycles metformin was demonstrated to significantly reduce the ovarian hyperstimulation syndrome (OHSS) rate in infertile patients with PCOS treated with gonadotropins.

The metformin regulating effect on the ovarian response was also observed in a randomized controlled trial (RCT) on young non-obese insulin-resistant women with PCOS receiving gonadotropins for mono-ovulation induction. In particular, metformin increased the mono-ovulatory cycles, the duration of stimulation and the amount of gonadotropins used, while it reduced the number of dominant follicles and the estradiol (E2) levels.

The aim of the present study was to evaluate the effect of metformin administration in high responder PCOS patients undergoing gonadotropins ovarian stimulation for IVF cycles.


Options:
A: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin, Placebo
B: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo administration | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Experimental group | Intervention Type: DRUG; Name: Placebo administration; Assigned to Arm(s): Control group
C: Arm Label: Atosiban used before embryo transfer; Type: EXPERIMENTAL; Interventions: Drug: Atosiban | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban used before embryo transfer
D: Arm Label: atosiban; Type: EXPERIMENTAL; Interventions: Drug: atosiban | Arm Label: 0.9% salain; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% saline | Intervention Type: DRUG; Name: atosiban; Assigned to Arm(s): atosiban | Intervention Type: DRUG; Name: 0.9% saline; Assigned to Arm(s): 0.9% salain

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antibiotic Treatment of Recurrent Episode of Asthma in Children - a Randomised, Case-controlled Study Within the COPSAC2010 Cohort (Asthma Begins in Childhood)
Brief Summary: Copsac has discovered that asthmatic exacerbations are as closely linked to bacterial as to viral infection. The current study will examine whether treatment of asthmatic exacerbations with macrolide antibiotics - in the abscence of clear clinical bacterial infection which would in any case precipitate antibiotic treatment - has an effect on either the particular episode, or subsequently. Macrolide antibiotics are chosen for ease of administration ensuring high compliance, antibiotic appropriacy, and anti-inflammatory properties.


Options:
A: Arm Label: Azythromycin (APRIL) and Prednisolone (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Azithromycin, Drug: Prednisolone | Arm Label: Azythromycin (APRIL) and Placebo (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Azithromycin, Drug: Placebo Prednisolone | Arm Label: Placebo (APRIL) and Prednisolone (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Other: Placebo Azithromycin | Arm Label: Placebo (APRIL) and Placebo (OCELOT); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Azithromycin, Drug: Placebo Prednisolone | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azythromycin (APRIL) and Placebo (OCELOT), Azythromycin (APRIL) and Prednisolone (OCELOT) | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Azythromycin (APRIL) and Prednisolone (OCELOT), Placebo (APRIL) and Prednisolone (OCELOT) | Intervention Type: OTHER; Name: Placebo Azithromycin; Assigned to Arm(s): Placebo (APRIL) and Placebo (OCELOT), Placebo (APRIL) and Prednisolone (OCELOT) | Intervention Type: DRUG; Name: Placebo Prednisolone; Assigned to Arm(s): Azythromycin (APRIL) and Placebo (OCELOT), Placebo (APRIL) and Placebo (OCELOT)
B: Arm Label: clarithromycin + fluticasone; Type: EXPERIMENTAL; Interventions: Drug: clarithromycin, Drug: fluticasone propionate | Arm Label: placebo + fluticasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone propionate, Drug: placebo clarithromycin | Intervention Type: DRUG; Name: clarithromycin; Assigned to Arm(s): clarithromycin + fluticasone | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): clarithromycin + fluticasone, placebo + fluticasone | Intervention Type: DRUG; Name: placebo clarithromycin; Assigned to Arm(s): placebo + fluticasone
C: Arm Label: Antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo mixture | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Antibiotics | Intervention Type: OTHER; Name: Placebo mixture; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Macrolides (azithromycin or clarithromycin); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antibiotic Treatment of Recurrent Episode of Asthma in Children - a Randomised, Case-controlled Study Within the COPSAC2010 Cohort (Asthma Begins in Childhood)
Brief Summary: Copsac has discovered that asthmatic exacerbations are as closely linked to bacterial as to viral infection. The current study will examine whether treatment of asthmatic exacerbations with macrolide antibiotics - in the abscence of clear clinical bacterial infection which would in any case precipitate antibiotic treatment - has an effect on either the particular episode, or subsequently. Macrolide antibiotics are chosen for ease of administration ensuring high compliance, antibiotic appropriacy, and anti-inflammatory properties.


Options:
A: Arm Label: Azithromycin (Zithromax); Type: EXPERIMENTAL; Interventions: Drug: Zithromax | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zithromax; Assigned to Arm(s): Azithromycin (Zithromax) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo mixture | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Antibiotics | Intervention Type: OTHER; Name: Placebo mixture; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Telithromycin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antibiotic Treatment of Recurrent Episode of Asthma in Children - a Randomised, Case-controlled Study Within the COPSAC2010 Cohort (Asthma Begins in Childhood)
Brief Summary: Copsac has discovered that asthmatic exacerbations are as closely linked to bacterial as to viral infection. The current study will examine whether treatment of asthmatic exacerbations with macrolide antibiotics - in the abscence of clear clinical bacterial infection which would in any case precipitate antibiotic treatment - has an effect on either the particular episode, or subsequently. Macrolide antibiotics are chosen for ease of administration ensuring high compliance, antibiotic appropriacy, and anti-inflammatory properties.


Options:
A: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: Clarithromycin, Drug: VCD induction therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: VCD induction therapy | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Clarithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VCD induction therapy; Assigned to Arm(s): Clarithromycin, Placebo
B: Arm Label: Biannual mass oral azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Biannual mass oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Biannual mass oral azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Biannual mass oral placebo
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 250 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin 250 mg; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo mixture | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Antibiotics | Intervention Type: OTHER; Name: Placebo mixture; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of LitramineTM in Reducing Body Weight in Overweight and Obese Subjects
Brief Summary: Preparations that bind to nutritional fat and inhibit its absorption could be decisively meaningful for the regulation of bodyweight or obesity. Further, it is known that soluble fibres gel and swell in the stomach and thereby induce a feeling of satiety or fullness after eating. Such effects are supposed to facilitate adherence to energy-restricted diets. The medical device to be investigated contains a patented formula of fibre complex having a high ability to bind to dietary fat.

Therefore, the rationale for this study is to confirm that Litramine's proven fat binding capacity to increase fat excretion and modulate the feeling of satiety will translate into measurable reduction in body weight. A double blind, randomized, placebocontrolled design has been chosen to assess the efficacy and safety of Litramine in overweight and obese subjects on a energy-restricted diet.


Options:
A: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin (glucophage) | Arm Label: Oral Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: oral placebo | Intervention Type: DRUG; Name: Metformin (glucophage); Assigned to Arm(s): Metformin | Intervention Type: OTHER; Name: oral placebo; Assigned to Arm(s): Oral Placebo
B: Arm Label: Glucosanol; Type: ACTIVE_COMPARATOR; Interventions: Device: Glucosanol | Intervention Type: DEVICE; Name: Glucosanol; Assigned to Arm(s): Glucosanol
C: Arm Label: Litramine; Type: EXPERIMENTAL; Interventions: Device: Litramine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo | Intervention Type: DEVICE; Name: Litramine; Assigned to Arm(s): Litramine | Intervention Type: DEVICE; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Behavioral: Lifestyle intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Lifestyle intervention | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Metformin, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Infant Feeding Experience of New Mothers - a Descriptive Pilot Study.
Brief Summary: Characterize a population-based sample of first-time expectant mothers with regards to maternal metabolic health and their infant feeding experience.


Options:
A: N/A
B: Arm Label: a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metoclopramide (Maxolon) | Arm Label: b; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: c; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metoclopramide (Maxolon) | Arm Label: d; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoclopramide (Maxolon); Assigned to Arm(s): a, c | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): b, d
C: Arm Label: Standard care plus metformin; Type: EXPERIMENTAL; Interventions: Behavioral: Standard care, Drug: Metformin | Arm Label: Standard Care plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard care, Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care plus placebo, Standard care plus metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Standard care plus metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard Care plus placebo
D: Intervention Type: DRUG; Name: domperidone; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Cash Transfer for the Prevention of HIV in Young South African Women
Brief Summary: Cash transfers to young women for staying in school and its effect on acquiring HIV


Options:
A: Arm Label: Multi-sectoral agricultural intervention; Type: EXPERIMENTAL; Interventions: Other: Multi-sectoral agricultural intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Multi-sectoral agricultural intervention; Assigned to Arm(s): Multi-sectoral agricultural intervention
B: Arm Label: no incentives; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: incentives for dietary self-monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: incentives for dietary self-monitoring | Arm Label: incentives for interim weight loss; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: incentives for interim weight loss | Arm Label: incentives for both; Type: EXPERIMENTAL; Interventions: Behavioral: incentives for both | Intervention Type: BEHAVIORAL; Name: incentives for dietary self-monitoring; Assigned to Arm(s): incentives for dietary self-monitoring | Intervention Type: BEHAVIORAL; Name: incentives for interim weight loss; Assigned to Arm(s): incentives for interim weight loss | Intervention Type: BEHAVIORAL; Name: incentives for both; Assigned to Arm(s): incentives for both
C: Arm Label: Cash transfer; Type: EXPERIMENTAL; Interventions: Other: Cash transfer | Arm Label: Comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cash transfer; Assigned to Arm(s): Cash transfer
D: Arm Label: A--Monthly cash transfers; Type: OTHER; Interventions: Behavioral: monthly cash transfer payments for attending school | Arm Label: B--No cash transfers; Type: OTHER; Interventions: Behavioral: monthly cash transfer payments for attending school, Behavioral: B--No cash transfers | Intervention Type: BEHAVIORAL; Name: monthly cash transfer payments for attending school; Assigned to Arm(s): A--Monthly cash transfers, B--No cash transfers | Intervention Type: BEHAVIORAL; Name: B--No cash transfers; Assigned to Arm(s): B--No cash transfers

Answer: D